Axonics Modulation Revenue and Competitors
Estimated Revenue & Valuation
- Axonics Modulation's estimated annual revenue is currently $161.9M per year.
- Axonics Modulation received $40.1M in venture funding in April 2018.
- Axonics Modulation's estimated revenue per employee is $266,787
- Axonics Modulation's total funding is $735.6M.
- Axonics Modulation's current valuation is $2.5B. (January 2022)
- Axonics Modulation has 607 Employees.
- Axonics Modulation grew their employee count by 15% last year.
What Is Axonics Modulation?
Axonics Modulation Technologies, Inc is a privately-held medical device company offering the smallest, longest-lived Sacral Neuromodulation System for patients suffering from Urinary and Fecal dysfunction. The Axonics r-SNM System is approved in Europe, Canada and Australia.keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Axonics Modulation News
... Size And Forecast | Nuvectra Corporation, Medtronic PLC, NeuroPace Inc, Laborie Inc, Axonics Modulation Technologies Inc., Nevro Corp.,...
Sacral Nerve Stimulation (SNS) Devices Market Growth 2022-2029| Key Players Axonics Modulation Technologies, IntraPace, Inc, Boston Scientific.
Axonics Modulation is working on a cup without handle with a 79.91 entry. See if it can break out in heavy trade.
Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel dysfunction, ...
Utrecht (The Netherlands), Cambridge (United States) - Axonics Modulation Technologies announced its Initial Public Offering and listing on the NASDAQ exchange. Shares in the IPO are issued to institutional investors in the US and Europe, raising gross proceeds of $120 million, representing one ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Axonics Modulation Funding
|2014-03-26||$32.6M||Undisclosed||Edmond de Rothschild Investment Partners||Article|
|2015-12-22||$38.5M||B||Advent Life Sciences||Article|